ALBERT

All Library Books, journals and Electronic Records Telegrafenberg

feed icon rss

Your email was sent successfully. Check your inbox.

An error occurred while sending the email. Please try again.

Proceed reservation?

Export
  • 1
    Electronic Resource
    Electronic Resource
    Springer
    Pharmaceutical research 12 (1995), S. 790-795 
    ISSN: 1573-904X
    Keywords: iontophoresis ; controlled release ; ion exchange ; cardiac arrhythmia ; percolation ; drug delivery implant
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology
    Type of Medium: Electronic Resource
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
  • 2
    ISSN: 1573-904X
    Keywords: controlled release ; lidocaine ; ventricular tachycardia ; arrhythmia
    Source: Springer Online Journal Archives 1860-2000
    Topics: Chemistry and Pharmacology
    Notes: Abstract Epicardial antiarrhythmic drug administration was studied as a therapeutic approach for experimental ventricular tachycardia (VT) in an open-chest dog model. Lidocaine-polyurethane matrices (28%, w/w) were formulated as a model system. Matrices were placed on the left ventricular epicardium in each of 23 anesthetized open-chest dogs with ouabain-induced VT, to evaluate effectiveness in restoring sinus rhythm. Conversion occurred in all animals treated with matrices containing 300 mg or more of lidocaine after 1.5 to 7.0 min. The matrix lidocaine content correlated linearly with the time required for conversion to sinus rhythm (r = 0.75, P = 0.0002); irrespective of matrix size the myocardial/plasma lidocaine ratio was 20.1 ± 4.2 (mean ± SD) at the time of conversion. In a separate series of five dogs without ventricular tachycardia, systolic wall thickening measured with sonomicrometers after 5 min of controlled-release lidocaine administration (500- to 1000-mg matrix lidocaine content, 7.48 ± 3.49-mg/kg dose) was only minimally diminished (−14.1%) and this effect was observed only at the site of matrix placement on the anterior-apical epicardium. In contrast, intracoronary injection of 0.3 or 1.0 mg/kg of lidocaine-HCl resulted in complete elimination of wall thickening or replacement by systolic thinning. Thus epicardial administration of lidocaine from polyurethane matrices was an effective means of treating ouabain-induced ventricular tachycardia. Regional myocardial function in the vicinity of the matrices was modified to a very limited degree, supporting the view that the matrices can be used safely, without serious risk to ventricular contractile performance.
    Type of Medium: Electronic Resource
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
  • 3
    Electronic Resource
    Electronic Resource
    New York, NY : Wiley-Blackwell
    Polymers for Advanced Technologies 3 (1992), S. 345-350 
    ISSN: 1042-7147
    Keywords: Transplantation ; Immunosuppression ; Controlled release drugs ; Steroids ; Cyclosporine ; Chemistry ; Polymer and Materials Science
    Source: Wiley InterScience Backfile Collection 1832-2000
    Topics: Chemistry and Pharmacology , Mechanical Engineering, Materials Science, Production Engineering, Mining and Metallurgy, Traffic Engineering, Precision Mechanics
    Notes: Systemic immunosuppression frequently results in severe side effects. To evaluate a method of limiting the adverse effects of immunosuppression, we implanted controlled release matrices containing cyclosporine-A (Cy) embedded (0.2 or 1 mg/kg/day released), steroid embedded (2%, 0.2% and 0.02% dexamethasone, Dex) or both (Cy 0.2 mg and Dex 0.2%) locally around the transplanted heart at the time of rat heterotopic (neck) heart transplants. Controls received empty (non-drug) matrix implants. To elucidate a local effect, additional groups received Cy (0.2 mg) or Dex (0.2%) matrix implanted in a subdermal distal leg pouch at the time of heart transplant, without a local neck implant. Rejection was determined by the lack of transplanted heart contractions. Recipient animals received no other form of immunosuppression.The Cy (0.2 mg) animals had whole-blood Cy levels monitored for 6 weeks following transplantation. Cy levels peaked at 7-10 days after transplant (119 ± 26 ng/ml) and decayed to 〈50 ng/ml by day 42. At no time did whole-blood Cy levels reach clinically significant levels. Additional animals had whole-blood, heart and kidney Cy levels measured at day 6 post-transplant. Both doses of local Cy demonstrated good survival benefit and were well absorbed locally, resulting in high Cy levels in heart tissue (〉9,000 ng/mg). Furthermore, while low-dose Cy (0.2 mg) demonstrated significant survival benefit, these animals had clinically negligible blood Cy levels on day 6 (〈100 ng/ml) and very low kidney Cy levels. Interestingly, the lowest dose of Dex demonstrated no survival benefit, while the mid- and high-Dex doses demonstrated good survival benefit: however, the high-Dex dose had poor wound healing. Cy and Dex combination did not increase efficacy, perhaps due to release problems from physicochemical interactions.Local immunosuppression with a controlled release matrix resulted in a significant survival advantage and was effective in delaying rejection. This approach may prove advantageous clinically, in extending transplantation and lessening immunosuppression side effects.
    Additional Material: 4 Ill.
    Type of Medium: Electronic Resource
    Location Call Number Expected Availability
    BibTip Others were also interested in ...
Close ⊗
This website uses cookies and the analysis tool Matomo. More information can be found here...